



Clinical trial results: Induction of Labour with a Foley catheter or oral Misoprostol at Term Summary

EudraCT number	2011-000026-30
Trial protocol	NL
Global end of trial date	10 October 2013

Results information

Result version number	v1 (current)
This version publication date	09 May 2021
First version publication date	09 May 2021
Summary attachment (see zip file)	Induction of labour at term with oral misoprostol versus a Foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial (1-s2.0-S0140673616000842-main.pdf)

Trial information

Trial identification

Sponsor protocol code	ABR35278
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	The Netherlands Trial Register : NTR3466

Notes:

Sponsors

Sponsor organisation name	AMC
Sponsor organisation address	Meibergdreef 9, Amsterdam, Netherlands, 1105AZ
Public contact	Verloskundig consortium, Academic medical centre, b.w.mol@amc.uva.nl
Scientific contact	Verloskundig consortium, Academic medical centre, b.w.mol@amc.uva.nl

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 February 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 October 2013
Global end of trial reached?	Yes
Global end of trial date	10 October 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess in term pregnant women with an unfavourable cervix (Bishop score <6) the effectiveness of induction of labor with a transcervical Foley catheter or oral misoprostol

Protection of trial subjects:

Through insurance/ IDMC rules - not sure what this question intends

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 July 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 1859
Worldwide total number of subjects	1859
EEA total number of subjects	1859

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1859
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All patients with a reason for induction of labour at term where screened if they were eligible

Period 1

Period 1 title	baseline period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Oral misoprostol

Arm description: -

Arm type	See article
----------	-------------

No investigational medicinal product assigned in this arm

Arm title	Foley catheter
------------------	----------------

Arm description: -

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Foley catheter
--	----------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Implant
----------------------	---------

Routes of administration	Vaginal use
--------------------------	-------------

Dosage and administration details:

See article

Investigational medicinal product name	misoprostol
--	-------------

Investigational medicinal product code	
--	--

Other name	
------------	--

Pharmaceutical forms	Tablet
----------------------	--------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

See article

Number of subjects in period 1	Oral misoprostol	Foley catheter
Started	932	927
Completed	932	927

Baseline characteristics

End points

End points reporting groups

Reporting group title	Oral misoprostol
Reporting group description: -	
Reporting group title	Foley catheter
Reporting group description: -	

Primary: Primary outcome for composite of neonatal asphyxia (arterial umbilical cord pH ≤ 7.05 or 5-min Apgar score < 7) or post-partum haemorrhage (estimated blood loss ≥ 1000 mL ascertained over 24 h post partum)

End point title	Primary outcome for composite of neonatal asphyxia (arterial umbilical cord pH ≤ 7.05 or 5-min Apgar score < 7) or post-partum haemorrhage (estimated blood loss ≥ 1000 mL ascertained over 24 h post partum)
End point description: See article	
End point type	Primary
End point timeframe: inclusion period	

End point values	Oral misoprostol	Foley catheter		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	924 ^[1]	921 ^[2]		
Units: 219				
number (not applicable)	113	106		

Notes:

[1] - See article

[2] - See article

Statistical analyses

Statistical analysis title	See article
Comparison groups	Oral misoprostol v Foley catheter
Number of subjects included in analysis	1845
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[3]
P-value	= 0.4
Method	t-test, 2-sided
Parameter estimate	Risk ratio (RR)
Point estimate	1.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.86
upper limit	1.31

Notes:

[3] - See article

Adverse events

Adverse events information

Timeframe for reporting adverse events:

inclusion period until 6 weeks after last recruitment

Adverse event reporting additional description:

52 serious adverse events were reported: 27 in the misoprostol group and 25 in the Foley catheter group

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	unknown
Dictionary version	0

Reporting groups

Reporting group title	Oral misoprostol
-----------------------	------------------

Reporting group description:

52 serious adverse events were reported: 27 in the misoprostol group and 25 in the Foley catheter group (appendix p 2). None were directly related to study procedures. 49 babies were admitted to neonatal intensive care units. Four babies died (one in the misoprostol group vs three in the Foley group): three because of lethal congenital malformations diagnosed after delivery (one vs two), and one because of asphyxia (none vs one). The mother of the child who died by asphyxia was induced because of polyhydramnios and gestational diabetes. After amniotomy, fetal bradycardia occurred, for which an emergency caesarean section was done. There was no hyperstimulation, no use of oxytocin, no cord prolapse, and no blood loss. Apgar score was 1 after 1 min, 0 after 5 min, and 1 after 10 min. Arterial umbilical cord pH was 6.99, base excess -16, and venous umbilical cord pH was 7.15, base excess -7.8. The child was admitted to neonatal intensive care for whole-body cooling. MRI 5 days after birth

Serious adverse events	Oral misoprostol		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 1845 (0.05%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Product issues			
See table 3, appendix p2	Additional description: see table 3, appendix p2		
subjects affected / exposed	1 / 1845 (0.05%)		
occurrences causally related to treatment / all	0 / 1845		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Oral misoprostol		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1845 (0.05%)		

Product issues see appendix article subjects affected / exposed occurrences (all)			
	Additional description: see appendix published artikel		
	1 / 1845 (0.05%) 1845		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported